SCC173
MCA205 Mouse Fibrosarcoma Cell Line
Mouse
Synonym(s):
MCA-205, MCA 205
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
UNSPSC Code:
41106514
eCl@ss:
32011203
NACRES:
NA.81
Recommended Products
product name
MCA205 Mouse Fibrosarcoma Cell Line, MCA205 mouse fibrosarcoma cell line is an excellent model for studying immune response to tumor cells and the development of targeted cancer immunotherapies.
biological source
mouse
technique(s)
cell culture | mammalian: suitable
shipped in
ambient
General description
Cancer immunotherapy is a rapidly expanding field that has produced significant advances in cancer treatment. Understanding the interactions of tumor cells with the immune system is crucial to the development of effective immunotherapeutic approaches. Fibrosarcoma is a rare yet aggressive soft-tissue sarcoma characterized by frequent tumor recurrences and a high degree of resistance to radio- and chemotherapy .
MCA-205 is a weakly immunogenic fibrosarcoma-derived cell line that has been used in many studies to induce tumor-reactive T lymphocytes, the key aspect of adoptive immunotherapy . MCA-205 cells are widely utilized as stimulators for inducing cytokine expression . The MCA-205 mouse fibrosarcoma cell line is an excellent model for studying the immune responses to tumor cells and for supporting the development of targeted cancer immunotherapies.
Source:
Non-GMO. MCA-205 was derived from 3-methylcholanthrene-induced fibrosarcoma in C57BL/6 mice. Tumors were maintained in vivo by serial subcutaneous transplantation in syngeneic mice and single-cell suspensions were prepared from solid tumors by enzymatic digestion . From these cells the MCA-205 cell line was established and maintained in vitro.
Source:
Non-GMO. MCA-205 was derived from 3-methylcholanthrene-induced fibrosarcoma in C57BL/6 mice. Tumors were maintained in vivo by serial subcutaneous transplantation in syngeneic mice and single-cell suspensions were prepared from solid tumors by enzymatic digestion . From these cells the MCA-205 cell line was established and maintained in vitro.
Cell Line Description
Cancer Cells
Application
MCA205 mouse fibrosarcoma cell line is an excellent model for studying immune response to tumor cells and the development of targeted cancer immunotherapies.
Research Category
Cancer
Oncology
Cancer
Oncology
This product is sold solely for research use per the terms of the “Restricted Use Agreement” which govern its use as detailed in the product Data Sheet or Certificate of Analysis. For information regarding any other use, please contact licensing@emdmillipore.com.
Quality
• Each vial contains ≥ 1X10⁶ viable cells.
• Cells are tested negative for infectious diseases by a Mouse Essential CLEAR panel by Charles River Animal Diagnostic Services.
• Cells are verified to be of mouse origin and negative for inter-species contamination from rat, chinese hamster, Golden Syrian hamster, human and non-human primate (NHP) as assessed by a Contamination CLEAR panel by Charles River Animal Diagnostic Services.
• Cells are negative for mycoplasma contamination
• Cells are tested negative for infectious diseases by a Mouse Essential CLEAR panel by Charles River Animal Diagnostic Services.
• Cells are verified to be of mouse origin and negative for inter-species contamination from rat, chinese hamster, Golden Syrian hamster, human and non-human primate (NHP) as assessed by a Contamination CLEAR panel by Charles River Animal Diagnostic Services.
• Cells are negative for mycoplasma contamination
Storage and Stability
Store in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
H Kagamu et al.
Cancer research, 56(19), 4338-4342 (1996-10-01)
The ability to generate a large number of tumor-reactive T lymphocytes is the most critical requirement for adoptive immunotherapy. Our laboratory has previously demonstrated that cells from tumor-draining lymph nodes (LNs) are an excellent source of tumor-reactive T lymphocytes. After
T Chou et al.
Journal of immunology (Baltimore, Md. : 1950), 140(7), 2453-2461 (1988-04-01)
We have previously established an in vitro sensitization (IVS) procedure with which lymphocytes from tumor-bearing mice could be expanded and sensitized to acquire antitumor reactivity capable of mediating the regression of established pulmonary metastases from the weakly immunogenic MCA 105
Klaire Yixin Fjæstad et al.
Oncogene, 41(9), 1364-1375 (2022-01-13)
The development of immune checkpoint inhibitors (ICI) marks an important breakthrough of cancer therapies in the past years. However, only a limited fraction of patients benefit from such treatments, prompting the search for immune modulating agents that can improve the
R J Barth et al.
Journal of immunology (Baltimore, Md. : 1950), 144(4), 1531-1537 (1990-02-15)
Tumor infiltrating lymphocytes (TIL) were cultured from multiple methylcholanthrene-induced sarcomas under four different conditions: either low-dose (10 U/ml) or high-dose (1000 U/ml) rIL-2 was used with Ag stimulation by irradiated autologous tumor and splenocytes starting either at day 1 or
Myrofora Panagi et al.
Nature communications, 13(1), 7165-7165 (2022-11-24)
Nano-immunotherapy improves breast cancer outcomes but not all patients respond and none are cured. To improve efficacy, research focuses on drugs that reprogram cancer-associated fibroblasts (CAFs) to improve therapeutic delivery and immunostimulation. These drugs, however, have a narrow therapeutic window
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service